Effect of lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 8, 2007, Pages 2943-2947

  Holdich, T ^a,c   Shiveley, L A ^b   Sawyer, J ^c,d  

^a Shire Pharmaceuticals   (United Kingdom)

^b SHIRE   (United States)

^c Prism Ideas   (United Kingdom)

^d Avexa   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APRICITABINE; AVX 754; BHC 10618; DEOXYCYTIDINE KINASE; EMTRICITABINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SPD 754; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CROSS-OVER STUDIES; DEOXYCYTIDINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; LAMIVUDINE; LEUKOCYTES, MONONUCLEAR; MALE; REVERSE TRANSCRIPTASE INHIBITORS; VOLUNTARY WORKERS;

EID: 34249314254     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01013-06     Document Type: Article

References (19)

1. Adams, J., J. Sawyer, and L. Shiveley. 2004. Abstr. 11th Conf. Retrovir. Opportunistic Infect., abstr. 599.
2. Balzarini, J., D. A. Cooney, M. Dalai, G. J. Kang, J. E. Cupp, E. DeClercq, S. Broder, and D. G. Johns. 1987. 2′,3′- Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. Mol. Pharmacol. 32:798-806.
3. Bethell, R. C., Y. S. Lie, and N. T. Parkin. 2005. In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs. Antivir. Chem. Chemother. 16:295-302.
4. Bethell, R., J. De Muys, J. Lippens, A. Richard, B. Hamelin, C. Ren, and P. Collins. 2007. In vitro interactions between apricitabine and other deoxycytidine analogues. Antimicrob. Agents Chemother. 51:XXX.
5. Blaise, P., P. Clevenbergh, D. Vaira, M. Moutschen, and P. Dellamonica. 2002. HIV resistance to antiretroviral drugs: mechanisms, genotypic and phenotypic resistance testing in clinical practice. Acta Clin. Belg. 57:191-201.
6. Cahn, P., I. Cassetti, R. Wood, P. Phanuphak, L. Shiveley, R. C. Bethell, and J. Sawyer. 2006. Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients. AIDS 20:1261-1268.
7. Cohen, C., C. Katiama, R. Murphy, J. Gathe, C. Brinson, G. Richmond, P.-M. Girard, J. Fessel, A. Liappis, E. Puglia, B. Rodwick, J. Nadler, W. O'Brien, K. Arasteh, M. Otto, S. Erickson-Viitanen, and R. Levy. 2005. Abstr. Third Int. AIDS Soc. Conf. HIV Pathog. Treat., abstr. WeOaLB0103, 2005.
8. de Muys, J. M., H. Gourdeau, N. Nguyen-Ba, D. L. Taylor, P. S. Ahmed, T. Mansour, C. Locas, N. Richard, M. A. Wainberg, and R. F. Rando. 1999. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2′-deoxy-3′-oxa-4′- thiocytidine. Antimicrob. Agents Chemother. 43:1835-1844.
9. Havlir, D. V., C. Tierney, G. H. Friedland, R. B. Pollard, L. Smeaton, J. P. Sommadossi, L. Fox, H. Kessler, K. H. Fife, and D. D. Richman. 2000. In vivo antagonism with zidovudine plus stavudine combination therapy. J. Infect. Dis. 182:321-325.
10. Ho, H. T., and M. J. Hitchcock. 1989. Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob. Agents Chemother. 33:844-849.
11. Hoggard, P., S. Khoo, M. Barry, and D. Back. 1996. Intracellular metabolism of zidovudine and stavudine in combination. J. Infect. Dis. 174:671-672.
12. Hoggard, P. G., S. D. Sales, S. Kewn, D. Sunderland, S. H. Khoo, C. A. Hart, and D. J. Back. 2000. Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitro. Antivir. Chem. Chemother. 11:353-358.
13. Hoggard, P. G., S. Kewn, M. G. Barry, S. H. Khoo, and D. J. Back. 1997. Effects of drugs on 2′,3′-dideoxy-2′,3′- didehydrothymidine phosphorylation in vitro. Antimicrob. Agents Chemother. 41:1231-1236.
14. Johnson, M. A., D. G. Johns, and A. Fridland. 1987. 2′,3′-Dideoxynucleoside phosphorylation by deoxycytidine kinase from normal human thymus extracts: activation of potential drugs for AIDS therapy. Biochem. Biophys. Res. Commun. 148:1252-1258.
15. Johnson, M. A., K. H. Moore, G. J. Yuen, A. Bye, and G. E. Pakes. 1999. Clinical pharmacokinetics of lamivudine. Clin. Pharmacokinet. 36:41-66.
16. Panel on Clinical Practices for Treatment of HIV Infection convened by the U.S. Department of Health and Human Services. 4 May 2006. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. [Online.] http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
17. Ray, A. S. 2005. Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase. AIDS Rev. 7:113-125.
18. +/-)-2′-deoxy-3′-oxa-4′- thiocytidine, dOTC]. Antivir. Chem. Chemother. 11:291-301.
19. Veal, G. J., M. G. Barry, S. H. Khoo, and D. J. Back. 1997. In vitro screening of nucleoside analog combinations for potential use in anti-HIV therapy. AIDS Res. Hum. Retrovir. 13:481-484.